GlassScriptPhysician profile
Don A Davis
NPI 1154528693
$10,554.26
in general payments reported to CMS, 2019-2025
31 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,104 · 2020: $1,166 · 2021: $804 · 2022: $847 · 2023: $2,039 · 2024: $1,673 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,407 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,406.82 |
| Education | $226.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,104.01 | 2019-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $1,078.88 | 2019-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $953.65 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Novartis Pharmaceuticals Corporation | $756.22 | 2019-2025 | |
| Abbott Laboratories | $637.67 | 2022-2024 | Fortify Assura, Allure Quadra, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $554.91 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $482.40 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $423.66 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $350.78 | 2019-2023 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $336.45 | 2021-2025 | |
| Philips North America LLC | $302.20 | 2020-2024 | (P84) Igt Devices Systems, (Cm9) Amb Mon & Diag Und |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $281.39 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $194.81 | 2019-2021 | |
| Pfizer INC. | $178.59 | 2020-2025 | |
| Penumbra, INC. | $118.50 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $110.71 | 2021-2024 | Linq II, Micra |
| Kiniksa Pharmaceuticals International, Plc | $78.51 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $67.60 | 2023-2024 | Inpefa |
| United Therapeutics Corporation | $67.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $65.77 | 2023 | |
| Kestra Medical Technology Services, INC. | $63.25 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $57.95 | 2019-2023 | Xarelto |
| Daiichi Sankyo INC. | $54.82 | 2022-2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $53.01 | 2020-2021 | |
| Esperion Therapeutics, INC. | $39.52 | 2024-2025 | Nexletol |
| Scpharmaceuticals INC. | $35.62 | 2024 | |
| Gilead Sciences, INC. | $35.25 | 2019 | |
| Impulse Dynamics (USA) INC. | $22.05 | 2023 | Optimizer |
| Shockwave Medical, INC | $16.78 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lilly USA, LLC | $16.44 | 2025 | Zepbound |
| Portola Pharmaceuticals, LLC | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.